Nonsteroidal anti-inflammatory drugs (NSAIDs) are increasingly implicated in cardiovascular morbidity [9] and Cyclooxygenase-2 (COX-2) selective inhibitors, a class of NSAIDs, have been, in particular, associated with increased risk of MI.[9], [10], [11], [12], [13], [14], [15], [16] Rofecoxib was withdrawn from the market after a randomized placebo-controlled trial revealed increased cardiovascular risk in patients with colorectal polyps.[17] Though similarly associated with cardiovascular risk [9], celecoxib is still prescribed widely. This evidence concerns the gene PTGS2 and polyp of large intestine.